Ultragenyx and Kyowa Kirin announce topline phase 3 study results
Ultragenyx, Kyowa Hakko Kirin announced the Phase 3 study of Crysvita® (burosumab) met its primary endpoint demonstrating that Crysvita was superior to oral phosphate and active vitamin D in improving rickets in children with X-linked hypophosphatemia (XLH) after 40 weeks of treatment. May 17, 2018